Bispecific antibodies: What future?;Anticorps bispécifiques: Quel avenir?

Medecine/Sciences

Volumn 25, Issue 12, 2009, Pages 1155-1157

  Pèlegrin, André ^a   Robert, Bruno ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 74749092161     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200925121155     Document Type: Review

References (18)

1. Kufer P, Lutterbüse R, Baeuerle PA. A revival of bispecific antibodies. Trends Biotechnol 2004 ; 22 : 238-44.
2. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 1985 ; 314 : 628-31.
3. Glennie MJ, McBride HM, Worth AT, Stevenson GT. Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments. J Immunol 1987 ; 139 : 2367-75.
4. Behar G, Sibéril S, Groulet A, et al. Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel 2008 ; 21 : 1-10.
5. Müller D, Kontermann RE. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr Opin Mol Ther 2007 ; 9 : 319-26.
6. Bargau R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008 ; 321 : 974-7.
7. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993 ; 363 : 446-8.
8. Willems A, Schoonooghe S, Eeckhout D, et al. CD3 x CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation. Cancer Immunol Immunother 2005 ; 54 : 1059-71.
9. Wu C, Ying H, Grinnell C, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007 ; 25 : 1290-7.
10. Baeuerle PA, Reinhardt C, Kufer P. BiTE : a new class of antibodies that recruit T-cells. Drugs of the Future 2008 ; 33 : 137-47.
11. Le Doussal JM, Martin M, Gautherot E, et al. In vitro and in vivo targeting af radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates : enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989 ; 30 : 1358-66.
12. Goldenberg DM, Chatal J, Barbet J, et al. Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther 2007 ; 2 : 19-31.
13. Goldenberg DM, Rossi EA, Sharkey RM, et al. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 2008 ; 49 : 158-63.
14. Robert B, Dorvillius M, Buchegger F, et al. Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA). Int J Cancer 1999 ; 81 : 285-91.
15. Dorvillius M, Garambois V, Pourquier D, et al. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens : ErbB-2 and carcinoembryonic antigen. Tumour Biol 2002 ; 23 : 337-47.
16. Robinson MK, Hodge KM, Horak E, et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 2008 ; 99 : 1415-25.
17. Lu D, Zhang H, Koo H, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005 ; 280 : 19665-72.
18. Qu Z, Goldenberg DM, Cardillo TM, et al. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood 2008 ; 111 : 2211-9.